Loading clinical trials...
Loading clinical trials...
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire.
Gluteal tendinopathy, also known as greater trochanteric pain syndrome, interferes with physical function and sleep, and is characterized by pain and tenderness over the greater trochanter.Clinical risk factors for the development of this condition include advanced age, female gender, back pain, overweight / obesity, poor abductor hip function, altered gait parameters, and psychological distress. The Victorian Institute of Sports Assessment for Gluteal tendinopathy (VISA-G) Questionnaire has recently designed as a patient-reported condition-specific outcome measurement tool to assess disability due to tendinopathy. VISA-G is scored between 0 and 100 (a higher score is expected) and consists of eight items covering three main areas (pain, function, and current activity level). Visual analog score for pain (0-10), the effect of pain on weight-bearing activities (0-30), and difficulty and / or function-related stairs use, including lying on the symptomatic side (0-10), climbing ramps (0-10), standing up without sitting (0-10), home or garden work (0-10) and regular exercise (0-10), physical activity and sports participation (0-10) are evaluated. The study is planned with 40 individuals with gluteal tendinopathy. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in VISA-G, Short Form-36, International Physical Activity Questionnaire, Numeric Rating Scale, Oswestry Disability Index, Oxford Hip Score and modified Harris Hip Score.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Halime ARIKAN
Ankara, None Selected, Turkey (Türkiye)
Start Date
January 1, 2022
Primary Completion Date
June 1, 2022
Completion Date
July 1, 2022
Last Updated
April 8, 2025
108
ACTUAL participants
Survey study
OTHER
Lead Sponsor
Gazi University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions